[2000年中国全国结核病流行病学调查中结核分枝杆菌的耐药情况]

[Drug resistance of Mycobacterium tuberculosis in a nationwide epidemiological survey in China in the year of 2000].

作者信息

Liu Yuhong, Jiang Guanglu, Zhao Liping, Fu Yuhong, Li Yunxu, Bi Zhiqiang, Wang Sumin

机构信息

Beijing Tuberculosis & Thoracic Tumor Research Institute, Beijing 101149, China.

出版信息

Zhonghua Jie He He Hu Xi Za Zhi. 2002 Apr;25(4):224-7.

PMID:12133331

Abstract

OBJECTIVE

To determine the state of anti-tuberculosis drug resistance, and to analyze the trend of drug resistance rate and assess its impact on National TB Programme (NTP).

METHODS

392 Mycobacterium tuberculosis (MTB) isolates from a nationwide epidemiological survey were subjected to susceptibility testing against 6 anti-tuberculosis drugs using the absolute concentration method.

RESULTS

The resistant rate to any drug was 27.8% in all MTB isolates, 18.6% in 263 new cases and 46.5% in 129 previously treated cases. Multi-drug resistant rate (MDR) was 10.7%. Initial and acquired MDR was 7.6% and 17.1%. Any resistance to INH, SM, RFP, PAS-Na, EMB and TB(1) was 17.6%, 17.3%, 16.6%, 2.8%, 1.5% and 1.3%, respectively. The resistant rates to 1, 2, 3 and 4 or more drugs were 7.6%, 4.6%, 4.6% and 1.9% in new cases and 14.7%, 19.4%, 10.1% and 2.3% in previously treated cases. The initial drug resistant rate did not show significant difference (P > 0.05) among different sex and age groups.

CONCLUSIONS

Compared to the previous data, the total drug resistance and initial drug resistance decreased significantly, but were still high. More attention should be paid to the trend of resistance of MTB to first-line drugs and especially the high incidence of MDR-TB.

摘要

目的

确定抗结核药物耐药状况，分析耐药率变化趋势并评估其对国家结核病防治规划（NTP）的影响。

方法

采用绝对浓度法，对全国流行病学调查中分离出的392株结核分枝杆菌（MTB）进行6种抗结核药物的敏感性检测。

结果

所有MTB分离株中对任意一种药物的耐药率为27.8%，263例新发病例中为18.6%，129例既往治疗病例中为46.5%。耐多药率（MDR）为10.7%。初始耐多药率和获得性耐多药率分别为7.6%和17.1%。对异烟肼、链霉素、利福平、对氨基水杨酸钠、乙胺丁醇和TB(1)的任何一种耐药率分别为17.6%、17.3%、16.6%、2.8%、1.5%和1.3%。新发病例中对1、2、3及4种或更多种药物的耐药率分别为7.6%、4.6%、4.6%和1.9%，既往治疗病例中分别为14.7%、19.4%、10.1%和2.3%。不同性别和年龄组的初始耐药率差异无统计学意义（P>0.05）。